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Abstract
Background: Jaffe-Campanacci syndrome is characterized by multiple non-ossifying fibromas, café-au-lait macules
and giant cell granulomas of the jaw. Even if the association between all these peculiar features and
neurofibromatosis type 1 have been described, it has not yet been clarified whether Jaffe-Campanacci syndrome
represents a distinct entity or it can be regarded as a neurofibromatosis type 1 subtype.
Case presentation: The patient here described is a young boy, who fulfilled the clinical diagnostic criteria for both
syndromes. He had a complex clinical history with café-au-lait macules, axillary and inguinal freckling, multiple non-
ossifying fibromas, giant-cell granuloma of the jaw, neurofibromas, plexiform fibroma, ocular Lisch nodules, optic
chiasmatic- hypothalamic glioma, pseudarthrosis, scoliosis, short stature, vascular anomalies, seizures. Molecular
analysis of the NF1 gene both on blood cells and non-ossifying fibroma’s biopsy tissue allowed the detection of a
novel variant within the coding region, NM_000267.3:c.2789_2791delATC(p.Tyr930_Pro931delinsSer), with loss of
heterozygosity (second hit mutation) in the non-ossifying fibroma.
Conclusion: This result indicates that every patient with clinical features of Jaffe-Campanacci syndrome should be
further evaluated to detect features related to neurofibromatosis type 1 and genetically investigated for mutations
in the NF1 gene, since this could lead to a definite diagnosis, but also could clarify and quantify the real genotype-
phenotype overlap between neurofibromatosis type 1 and Jaffe-Campanacci syndrome.
Keywords: Neurofibromatosis type 1, Jaffe-Campanacci syndrome, Non-ossifying fibromas, Giant cell granulomas of
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© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: silvia.vannelli@unito.it
1Pediatric Endocrinology Unit, Department of Public Health and Pediatric
Sciences, Regina Margherita Children’s Hospital, University of Turin, Turin,
Italy
Full list of author information is available at the end of the article
Vannelli et al. Italian Journal of Pediatrics           (2020) 46:58 
https://doi.org/10.1186/s13052-020-0813-9
Background
The eponymous Jaffe–Campanacci syndrome (JCS) was
coined in 1982 by Mirra [1] on the basis of a set of signs
and symptoms firstly described by Jaffe [2] and Campa-
nacci [3], encompassing café-au-lait macules (CALMs),
multiple non-ossifying fibromas (NOFs) and central
giant cell granulomas (CGCG) of the jaw [1, 2, 4]. Other
features variably included in the JCS are mental retard-
ation, hypogonadism, cryptorchidism, several congenital
ocular anomalies and cardiovascular malformations (i.e.
mitral insufficiency and stenosis of the aortic isthmus)
[3]. Single reports have further described precocious pu-
berty, alopecia, kyphoscoliosis, mega-ureter, chylothorax
and chylopericardium [3, 4] within JCS.
Since its first description by Jaffe, it has been debated
whether this syndrome represents a distinct entity or is a
neurofibromatosis type 1 (NF1) subtype. The clinical
diagnosis of NF1 is based on the presence of six or more
CALMs > 5mm in prepubertal and > 15mm in postpub-
eral individuals, two or more neurofibromas of any type
or one plexiform neurofibroma, freckling in the axillary
or inguinal regions, optic glioma, two or more Lisch
nodules, distinctive osseous lesion (such as sphenoid
dysplasia or tibial pseudarthrosis), a first-degree relative
harboring NF1 gene mutation [5].
Indeed, the three main signs of JCS (CALMs, NOFs
and CGCG) have also been reported in NF1 patients and
JCS case reports often lacked NF1 clinical or genetic ex-
clusion [6].
Case presentation
The first clinical manifestation in our patient was the ap-
pearance of CALMs at 1 month of age, afterwards in-
creased in number until 20 macules with a diameter
greater than 1.5 cm. Axillary and inguinal freckling,
widespread neurofibromas (cutaneous and maculopapu-
lar in the trunk and limbs, subcutaneous and nodular in
the head), an axillary plexiform neurofibroma and ocular
Lisch nodules were subsequently detected, leading to the
clinical diagnosis of NF1. In the second year of life a vo-
luminous optic chiasmatic-hypothalamic glioma was
found; surgery was excluded in consideration of the
localization and large extension of the mass that was
successfully treated with chemotherapy. At 9 years of age
a spontaneous fracture occurred at lower limbs; X-rays
revealed bilateral multiple lytic areas in the distal part of
femur, distal and proximal part of tibia and fibula. Bone
analysis on a sample taken during the surgery led to the
diagnosis of NOFs. NF1 gene analysis both on blood
cells and NOF tissue allowed to detect a novel variant:
NM_000267.3:c.2789_2791delATC(p.Tyr930_Pro931de-
linsSer), “likely pathogenic” according to ACMG-AMP
guidelines (criteria PM1+ PM2+ PM4+ PP3+ PP4) [7]
with also loss of heterozygosity in the NOF. The parents
did not show signs of NF1 or JCS but they decided not
to undergo molecular analysis. Family history was
unremarkable.
The monitoring of NOFs showed that they evolved
into spontaneous fractures in the right femur, right hu-
merus, right tibia, left femur (Fig. 1); furthermore, over
Fig. 1 NOFs in the right leg
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time pseudarthrosis on both tibias, mild scoliosis and
valgus deviation of the left knee have developed.
At the age of 11, a lesion appeared on the oral cavity
floor, CGCG of the jaw was diagnosed from a bioptic
specimen (Fig. 2) and then surgically removed.
The boy had short stature; the height was between the
50° and the 75° percentile according to the standards of
Tanner [8] up to 9 years of age, then the growth rate de-
creased due to growth hormone deficiency, likely related
to the previous optic chiasmatic- hypothalamic glioma.
At 16.7 years of age the height was 162.5 cm, just above
the 3rd percentile, not reaching the target height. Add-
itional features displayed by our patients were hyperten-
sion, due to stenosis of the renal arteries and treated
with two stenting procedures, abdominal aorta stenosis
with coarctation treated with aortic angioplasty, diffuse
unidentified bright objects (UBOs) in cerebral magnetic
resonance and seizures (at 5 years of age with left tem-
poroparietal electroencephalographic abnormalities,
treated with oxcarbazepine for 4 years). At the moment,
the boy is 17 years old and is on a multidisciplinary fol-
low up.
Discussion
By describing the new clinical entity for the first time,
Jaffe suggested that the disorder was an unusual form of
neurofibromatosis [2]. JCS reports have then been pre-
sented for years as distinct forms from NF1 [4, 9–15]. In
the 2013 “WHO Classification of tumours of soft tissue
and bone”, JCS is therefore defined as the association of
NOFs and NF1 [16], but NOFs, considered for years as a
distinctive feature of JCS, have also been reported in
NF1 patients [17–29].
Fibrous cortical defects and NOFs are indeed common
bone focal lesions, with an estimated rate up to 30% of
the asymptomatic population in the first and second
decade of life [30]. They are usually incidentally found in
X-rays performed for injuries and belong to the group of
developmental abnormalities [30]. In a series of 900 pa-
tients with biopsy-proven NOFs, Moser et al. found 72
cases (8%) with multiple lesions and the incidence of
neurofibromatosis in presence of multiple NOFs was 5%
[18]. Mankin et al. reported 401 patients with bone le-
sions described as NOFs and fibrous cortical defects, but
only two of them meeting the criteria for JCS [31].
NOFs in JCS cases are mainly large and located in the
metaphyseal region, with high number of anatomic sites
involved and multiple small fractures, irregular ossifica-
tion and cortical irregularity [31]. The most common
sites at which NOFs occur are distal femur, proximal
and distal tibia, proximal humerus, fibula and radius,
with frequent fractures and some deformities of the in-
volved bones [31]. In JCS the fracture risk appears to be
high, as more than half of the patients will experience at
least one fracture; it may be related to the lesion fea-
tures, which are multiple and large, with thinning of the
cortex and weakening of the weight-bearing bones [9].
The histology of NOFs is characterized by fibroblastic,
often highly cellular, collagenous stromal tissue with few
multicentric giant cells along with foci of xanthomatous
reaction and few foamy histiocytes; sites of necrosis may
be observed [31].
Baumhoer et al. found heterozygous NF1 gene muta-
tion in two NOFs sample in patients with NF1.
[32]. Colby et al. described 4 patients with NOFs, who
met the criteria of both JCS and NF1; the molecular test
of the NF1 gene was performed in one patient (only in
the blood), showing partial deletion of the gene [17]; the
author thus suggested a genetic evaluation in all patients
diagnosed with JCS and a radiographic screening of both
knees to detect NOFs in NF1 during early adolescence
or adulthood [17]. However, ionizing radiations should
be used with caution in NF1 patients, especially in paedi-
atric population and therefore clinicians should keep in
mind the association between NF1 and NOFs and defin-
itely consider radiographic examination in case of sug-
gestive symptoms.
The other key feature of JCS, presented by our patient,
is CGCG involving the jaw. In the Stewart’s series, som-
atic second-hit mutations in the NF1 gene were detected
in two giant cell lesions from two unrelated patients
with the main features of JCS [33]. CGCG has also been
described in NF1 patients [34–43].
Some authors have hypothesized that the CGCG rep-
resented the mandibular manifestation of the long bone
Fig. 2 Giant-cell granuloma of the jaw
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NOF, but Slootweg, performing a histologic comparison
of a significant number of lesions, concluded that, al-
though they may exhibit histologically similar areas, the
two entities are separate [44]. He evidenced important
differences: the fibrous stroma with the cells arranged in
whorled bundles, which was the hallmark of NOFs, was
observed in some, but not all CGCG (and in CGCG it
was only focally); foam cells were found in almost a
quarter of the NOFs but almost universally absent in
CGCG; bone formation played a major part in CGCG
whereas in NOFs it was nearly absent [44].
The third main feature of JCS is CALM, which is also
one of the main signs of NF1. The pathophysiology is
still largely unknown. De Schepper et al. reported that in
NF1 patients, between normal skin and CALMs, higher
density of melanocytes was present in CALMs; CALMs
in control and NF1 patients differed in melanocyte dens-
ity, melanin content and melanogenesis of melanocytes
and in the amount of stem cell factor secreted by fibro-
blasts, which are all higher in NF1 [45].
JCS in not the only syndrome showing phenotypic over-
lap with NF1: other examples are represented by the
‘neuro-cardio-facial-cutaneous’ syndrome (with a variable
degree of cognitive impairment, facial dysmorphism, con-
genital heart defects and skin abnormalities), related to
mutations in the genes that encode other components of
the RAS-MAPK pathway, such as PTPN11, KRAS8 and
SOS1 in Noonan syndrome, PTPN11 in LEOPARD syn-
drome, HRAS13 in Costello syndrome, KRAS14, BRAF14,
15, MEK1 and MEK2 in cardio-facio-cutaneous syndrome
[46]. Another noteworthy example is Legius syndrome,
due to SPRED1 mutations (RAS-MAPK pathway), whose
phenotype includes café-au-lait spots, freckling and lacks
the non-pigmentary manifestations of NF1; additional
clinical manifestations reported commonly include lip-
omas, macrocephaly, learning disabilities, attention deficit,
hyperactivity disorder, developmental delays, Noonan
syndrome-like facies and, less frequently, short stature,
pectus anomalies, depigmented macules, vascular lesions,
headaches, hearing loss, seizures, polydactyly, scoliosis.
[46, 47]. Different signs of this syndrome are present
also in our patient, so it is evident that overlapping
phenotype can complicate the diagnosis.
The patient reported in our case fulfilled NF1 diagnos-
tic criteria. He displayed café au lait macules, neuro-
fibromas, plexiform neurofibroma, freckling in the
axillary and inguinal regions, optic chiasmatic- hypothal-
amic glioma, Lisch nodules, osseous lesion such as tibial
pseudarthrosis; he then developed scoliosis, UBOs, sei-
zures, short stature, hypertension due to renovascular
diseases, mid-aortic syndrome. All these features had
previously been described in patients with NF1 [5], but
it is very difficult to find them all in a single subject,
which also showed also the JCS main signs in a severe
form with a high number of NOFs. Here we reported an
extremely severe case, which required a multidisciplinary
approach with molecular analysis. A mutation on the
NF1 gene, not yet reported in NF1, was detected either
in blood cells and NOF’s tissue, pointing out the NF1
gene alterations can be responsible for all the clinical
features, ascribed either to the JCS or NF1 conditions.
Pathogenic germline NF1 mutations were identified by
Stewart et al. in 13 out 14 patients with multiple café-
au-lait macules and multiple NOFs or giant cell lesions
(none of the mutations were detected directly on NOF
tissue) [33]. All 13 subjects also fulfilled the diagnostic
criteria for NF1. Consequently, Stewart et al. suggested
that many JCS cases may actually have NF1 and they
proposed a clinical algorithm for patients with NOFs
and/or giant cell lesions [33]. They also recommend that
the term “Jaffe–Campanacci syndrome” should only be
used for patients with multiple CALMs, multiple NOFs,
and/or CGCG who also lack a germline NF1 mutation
or who lack evidence of an other recognized disorder as-
sociated with NOFs and CGCG [33].
The true incidence of NF1 mutations in JCS patients
still remains uncertain, since molecular studies on the
NF1 gene have not been so far performed in most JCS
patients.
The cellular and molecular pathophysiology of the dif-
ferent features of the NF1 disease is not completely
understood. Factors that complicate his understanding
include the large size of the NF1 gene, the presence of
several NF1 pseudogenes, the complex interactions be-
tween cell types, and the NF1-haploinsufficient state of
all cells in the body [48]. For some features, a somatic
inactivation of the wild type NF1 allele was detected, ac-
cording to the “two- hit theory”: the first mutations in
the NF1 gene could occur during embryonic develop-
ment, generating NF1 mosaic patients and therefore an-
other somatic NF1 mutations could represent the
“second hit”, which inactivates the wild type NF1 allele
in NF1 heterozygous patients [49]. Maertens et al. dem-
onstrated the biallelic inactivation of the NF1 gene in
melanocytes in NF1-related CALMs and evidenced that
the mosaic phenotype reflected the embryonic timing
and, accordingly, the neural crest–derived cells in the
somatic NF1 mutation [48]. Other authors have de-
scribed the same “second hit” mechanism with biallelic
inactivation on NF1 gene in other tissues and related tu-
mors [33, 38, 49, 50], including giant cell granulomas of
the jaw in patients with NF1 [38] and JCS [33]. In our
case, the molecular analysis of NF1 gene in the NOF de-
tected NF1 mutation and loss of heterozygosity (only the
mutant allele was present), which should be considered
as the “second hit”.
In NF1, given the paucity of NF1 genotype–phenotype
correlations, it has been proposed that, besides a
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phenotypic heterogeneity among the different variants
within the gene, a role of modifier genes could explain
the variability of clinical manifestations [50]. Many ques-
tions remain about the relevance of possible interaction
partners and the function of neurofibromin protein do-
mains in NF1 mutation [50]. All these processes may ex-
plain the different presentation of NF1 and maybe the
characteristics of syndromes with phenotypic overlap, as
JCS. Therefore, in these conditions genetic analysis can
lead to the correct diagnosis, thus allowing also appro-
priate follow-up protocols as well.
Conclusions
Here is described a patient displaying clinical features of
both NF1 and JCS and a NF1 gene mutation detected on
blood cells and NOF’s biopsy tissue, with loss of hetero-
zygosity in the NOF. These findings support the thesis
that JCS could be considered a NF1 subtype. Clinicians
must always consider the possible presence of NOFs and
CGCG in patients with NF1, paying attention to specific
symptoms. On the other hand, in patients with signs of
JCS, deeply evaluation is crucial to detect other features
related to NF1. In consideration of the clinical and mo-
lecular overlapping characteristics between JCS and
NF1, we strongly recommend to investigate for NF1
gene mutations in patients diagnosed as having the JCS.
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